Ewgeni Jakubovski

2 papers in the library · 36 citations · publishing 2017-2023

Papers

Sort Most recent Most cited

CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders - Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study.

Psychiatry Research May 1, 2023 Kirsten R Müller-vahl, Anna Pisarenko, Natalia Szejko et al. 36 citations

Preliminary data suggest that cannabis-based medicines might be a promising new treatment for patients with Tourette syndrome (TS)/chronic tic disorders (CTD) resulting in an improvement of tics, comorbidities, and quality of life. This randomized, multicenter, placebo-controlled, phase IIIb study aimed to examine efficacy and safety of the cannabis extract nabiximols in adults with TS/CTD (n =...

DOI: 10.1016/j.psychres.2023.115135 Full text ADHD Cannabis-based medicine Nabiximols OCD +3

Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial.

Neuropsychopharmacology August 29, 2017 Jerome H Taylor, Angeli Landeros‐Weisenberger, Catherine Coughlin et al.

Many patients with social anxiety disorder (SAD) experience inadequate symptom relief from available treatments. Ketamine is a potent N-methyl-D-aspartate receptor antagonist with a potentially novel mechanism of action for the treatment of anxiety disorders. Therefore, we conducted a double-blind, randomized, placebo-controlled crossover trial in 18 adults with DSM-5 SAD and compared the...

DOI: 10.1038/npp.2017.194 Full text Ketamine Humans Receptors, n-methyl-d-aspartate Anti-anxiety agents +5